netFormulary NHS
NHS NEL
Demonstration Formulary
 Search
 Formulary Chapter 6: Endocrine system - Full Chapter
Notes:

 

 

 
Chapter Links...
Link   NICE NG28: Type 2 diabetes in adults: management
Link   DVLA guidance
Link   NICE Guidance on prescribing
 Details...
06.01.02.03  Expand sub section  Other antidiabetic drugs
06.01.02.03  Expand sub section  DPP-4 inhibitors
06.01.02.03  Expand sub section  Alpha glucosidase inhibitors
06.01.02.03  Expand sub section  GLP-1 mimetics
06.01.02.03  Expand sub section  DPP4 inhibitors (gliptins) to top
Sitagliptin
View adult BNF View SPC online View childrens BNF 		First Choice
Green

To be used in line with NICE

First line treatment option where a DPP-4 inhibitor is indicated.


No significant clinical benefit when used in combination with Insulin – avoid using together

 
Link  MHRA: Dipeptidylpeptidase-4 inhibitors: risk of acute pancreatitis
 
Alogliptin (Vipidia®)
View adult BNF View SPC online View childrens BNF 		Formulary
Green

In line with NICE No significant clinical benefit when used in combination with Insulin – avoid using together 

 
Link  MHRA: Dipeptidylpeptidase-4 inhibitors: risk of acute pancreatitis
 
Linagliptin
View adult BNF View SPC online View childrens BNF 		Formulary
Green

In line with NICE
Linagliptin has no significant clinical benefit or renoprotective effect in patients with CKD.

Sitagliptin should be used first line at the appropriate renal dose
where a DPP4 inhibitor is indicated


No significant clinical benefit when used in combination
with Insulin – avoid using together

 
Link  MHRA: Dipeptidylpeptidase-4 inhibitors: risk of acute pancreatitis
 
06.01.02.03  Expand sub section  SGLT2 inhibitors
06.01.02.03  Expand sub section  GLP1 agonists
06.01.02.03  Expand sub section  Meglitinides
06.01.02.03  Expand sub section  SGL2 inhibitors
06.01.02.03  Expand sub section  Other to top
06.01.02.03  Expand sub section  Thiazolidinediones
 ....
 Non Formulary Items
Sitagliptin  (Januvia®)

View adult BNF View SPC online View childrens BNF 		Non Formulary
Black
Link  MHRA: Dipeptidylpeptidase-4 inhibitors: risk of acute pancreatitis
  
Key
Restricted Drug Restricted Drug
Unlicensed Drug Unlicensed
click to search medicines.org.uk
 Link to adult BNF
click to search medicines.org.uk
 Link to children's BNF
click to search medicines.org.uk
 Link to SPCs
Cytotoxic Drug
 Cytotoxic Drug
CD
 Controlled Drug
High Cost Medicine
 High Cost Medicine
Cancer Drugs Fund
 Cancer Drugs Fund
NHSE
 NHS England
Homecare
 Homecare
ICB
 ICB
Green Low Carbon

Low carbon footprint
Amber Medium Carbon

Medium carbon footprint
Red High carbon footprint

High carbon footprint
Status Description

Green

 Medicines which are suitable for initiation and maintenance prescribing by primary and secondary care clinicians. These medicines should be initiated and prescribed within their licensed indications  

Amber Initiation

 Amber Specialist Initiation: Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing when appropriate. This may be supported by a RICaD, annotated within the formulary entry.  

Amber SC

 Amber Shared Care: Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing, in accordance with an ESCA, annotated within the formulary entry.  

Amber Recommended

 Amber Specialist Recommendation: Initiation and maintenance of prescribing in Primary Care following recommendation from a specialist.  

Red

 Medicines for initiation and maintenance prescribing by Specialists (hospital or GPs with Special Interest) only  

Grey

 Positive NICE TA and /or awaiting local clarification on place in therapy; Please contact your Medicines Optimisation team for more information.  

Black

 Non-formulary Medicines which APC/Trust DTC has actively reviewed and do not recommend for use.  

Multiple

 Check Notes as varies across the area  

netFormulary